Forum for Science, Industry and Business

Sponsored by:     3M 
Search our Site:

 

Molecular analyses of leukemia patients suggest strategies for better treatments

08.04.2004


Review article from St. Jude Children’s Research Hospital in New England Journal of Medicine



The cure rate for pediatric acute lymphoblastic leukemia (ALL) might continue to rise with improved use of conventional therapies. But even more effective and less toxic therapies based on genetic and pharmacogenetic studies might one day push the success rate close to 100 percent, according to an article published by investigators at St. Jude Children’s Research Hospital in the April 8 issue of the New England Journal of Medicine.

The St. Jude researchers base their prediction on their review of the current and evolving state of ALL diagnosis and treatment. ALL is a cancer in which an excess number of immature and non-functional white blood cells overwhelm the body’s ability to make normal blood cells in the bone marrow. It is the most common type of cancer in children, with about 3,000 new cases each year in the United States alone. The survival has rate increased from 4 percent--when St. Jude opened in 1962--to 80 percent today, following the development of protocol-based treatment at St. Jude that combined different anti-ALL drugs and revolutionized the treatment of ALL.


"The substantial progress in ALL treatment being made today at St. Jude and other institutions reflects not only a more effective use of combining traditional anti-leukemic drugs, but also significant breakthroughs in genetic studies of ALL patients," said Ching-Hon Pui, M.D., director of the St. Jude Leukemia Lymphoma division and the F.M. Kirby Clinical Research Professor for the American Cancer Society.

A key advantage to the genetic approach to ALL treatment is the increasing ability of physicians to identify which gene mutations are linked to increased or decreased responsiveness to anti-leukemic drugs. This information is helping researchers to identify children who have particularly drug-resistant forms of ALL, as well as patients who are more susceptible to the toxicities of specific treatments. The new approach is also guiding development of new drugs that target specific cell molecules, thus avoiding the toxic side effects caused by chemotherapy.

Clinical trials are underway to test the safety and efficacy of drugs targeting a variety of gene mutations. In addition, St. Jude researchers are conducting Phase I clinical trials with investigational drugs to treat cases of ALL that have resisted previous therapies.

Fueling this surge of genetic studies of ALL is the use of DNA microarrays, a technology that permits researchers to analyze simultaneously the expression of thousands of genes. This technology accurately identifies known variations of ALL and provides key insights into their biology and their responses to therapy.

Microarray studies are disclosing the genes making up specific biochemical events leading to ALL, as well as the changes in gene expression caused by specific treatments. When validated by clinical trials, such information will enable physicians to predict with great accuracy how a specific patient will respond to a particular treatment, and to design treatments that will be the most effective but least toxic.

Breakthroughs in genetic analysis of ALL have also provided evidence that some cases of ALL might be due, in part, to a developmental error or exposure of the fetus to mutagens--chemicals that cause gene mutations. The recognition that environmental factors might play a role in the development of ALL has prompted large-scale epidemiological studies in the United States and Britain to determine the affect, if any, exposure to chemicals, viruses, bacteria or ionizing radiation.

The authors conclude that genetic studies of leukemic cells will disclose the mechanism of ALL development and lead to the identification of targets for specific treatments. Studies of genes involved in the metabolism and the effects of chemotherapy and environmental agents will also help develop optimal treatment, and may even provide important clues for the cause of leukemia. Together, these advances might one day permit physicians to cure all patients, regardless of the type of ALL they have, and might even lead to ways to prevent this disease.


Other authors of this review are Mary Relling, Pharm.D., and James Downing, M.D.

Bonnie Cameron | EurekAlert!
Further information:
http://www.stjude.org

More articles from Health and Medicine:

nachricht Millions through license revenues
27.04.2017 | Rheinische Friedrich-Wilhelms-Universität Bonn

nachricht New High-Performance Center Translational Medical Engineering
26.04.2017 | Fraunhofer ITEM

All articles from Health and Medicine >>>

The most recent press releases about innovation >>>

Die letzten 5 Focus-News des innovations-reports im Überblick:

Im Focus: Making lightweight construction suitable for series production

More and more automobile companies are focusing on body parts made of carbon fiber reinforced plastics (CFRP). However, manufacturing and repair costs must be further reduced in order to make CFRP more economical in use. Together with the Volkswagen AG and five other partners in the project HolQueSt 3D, the Laser Zentrum Hannover e.V. (LZH) has developed laser processes for the automatic trimming, drilling and repair of three-dimensional components.

Automated manufacturing processes are the basis for ultimately establishing the series production of CFRP components. In the project HolQueSt 3D, the LZH has...

Im Focus: Wonder material? Novel nanotube structure strengthens thin films for flexible electronics

Reflecting the structure of composites found in nature and the ancient world, researchers at the University of Illinois at Urbana-Champaign have synthesized thin carbon nanotube (CNT) textiles that exhibit both high electrical conductivity and a level of toughness that is about fifty times higher than copper films, currently used in electronics.

"The structural robustness of thin metal films has significant importance for the reliable operation of smart skin and flexible electronics including...

Im Focus: Deep inside Galaxy M87

The nearby, giant radio galaxy M87 hosts a supermassive black hole (BH) and is well-known for its bright jet dominating the spectrum over ten orders of magnitude in frequency. Due to its proximity, jet prominence, and the large black hole mass, M87 is the best laboratory for investigating the formation, acceleration, and collimation of relativistic jets. A research team led by Silke Britzen from the Max Planck Institute for Radio Astronomy in Bonn, Germany, has found strong indication for turbulent processes connecting the accretion disk and the jet of that galaxy providing insights into the longstanding problem of the origin of astrophysical jets.

Supermassive black holes form some of the most enigmatic phenomena in astrophysics. Their enormous energy output is supposed to be generated by the...

Im Focus: A Quantum Low Pass for Photons

Physicists in Garching observe novel quantum effect that limits the number of emitted photons.

The probability to find a certain number of photons inside a laser pulse usually corresponds to a classical distribution of independent events, the so-called...

Im Focus: Microprocessors based on a layer of just three atoms

Microprocessors based on atomically thin materials hold the promise of the evolution of traditional processors as well as new applications in the field of flexible electronics. Now, a TU Wien research team led by Thomas Müller has made a breakthrough in this field as part of an ongoing research project.

Two-dimensional materials, or 2D materials for short, are extremely versatile, although – or often more precisely because – they are made up of just one or a...

All Focus news of the innovation-report >>>

Anzeige

Anzeige

Event News

Fighting drug resistant tuberculosis – InfectoGnostics meets MYCO-NET² partners in Peru

28.04.2017 | Event News

Expert meeting “Health Business Connect” will connect international medical technology companies

20.04.2017 | Event News

Wenn der Computer das Gehirn austrickst

18.04.2017 | Event News

 
Latest News

Wireless power can drive tiny electronic devices in the GI tract

28.04.2017 | Medical Engineering

Ice cave in Transylvania yields window into region's past

28.04.2017 | Earth Sciences

Nose2Brain – Better Therapy for Multiple Sclerosis

28.04.2017 | Life Sciences

VideoLinks
B2B-VideoLinks
More VideoLinks >>>